Trial Profile
Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Levofloxacin (Primary) ; Amoxicillin; Lansoprazole; Metronidazole
- Indications Helicobacter pylori infections
- Focus Therapeutic Use
- 02 Feb 2016 Status changed from active, no longer recruiting to completed, according to results published in the American Journal of Gastroenterology.
- 02 Feb 2016 Primary endpoint of eradication rate in the second line therapy has been met, according to results published in the American Journal of Gastroenterology.
- 02 Feb 2016 Results published in the American Journal of Gastroenterology